Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caverstem is an autologous bone marrow concentrate (BMAC) therapy developed by Creative Medical Technologies for the treatment of erectile dysfunction (ED). The procedure involves harvesting a patient's own bone marrow, concentrating the regenerative cells—including mesenchymal stem cells and growth factors—and injecting the concentrate intra-cavernously into the penis. The therapy is designed to address the underlying biological causes of ED, such as the loss of corporal smooth muscle and vascular insufficiency, by promoting angiogenesis and tissue repair. It is primarily positioned as a treatment for patients who are non-responsive to standard pharmacological interventions like PDE5 inhibitors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Caverstem.